2025 France Anti-Obesity Drugs Market Revenue Opportunities Report
Description
The 2025 France Anti-Obesity Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Obesity Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the anti-obesity drugs market in France are Novo Nordisk, Eli Lilly, Hoffmann-La Roche, and Pfizer. Novo Nordisk dominates the market with its GLP-1 receptor agonist drugs, especially Wegovy and Ozempic, which have seen rapid adoption due to their efficacy in weight loss, driving strong sales in France and across Europe. Eli Lilly is a key competitor with its tirzepatide-based drugs Mounjaro and Zepbound, which demonstrate superior weight loss effects and are projected to outperform Novo Nordisk’s products in the near future.
Hoffmann-La Roche is also actively involved, having partnered with Zealand Pharma to develop novel anti-obesity drugs like petrelintide, targeting improved weight management and combination therapies. Pfizer has ongoing developments with GLP-1 receptor agonists such as danuglipron, though it discontinued one candidate in 2025, continuing its research pipeline for oral treatments that could increase accessibility in France and Europe. These companies are driving France's fast-growing anti-obesity drug market, projected to reach USD 742.8 million by 2030 with robust CAGR growth fueled by increasing obesity prevalence and healthcare initiatives.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Obesity Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the anti-obesity drugs market in France are Novo Nordisk, Eli Lilly, Hoffmann-La Roche, and Pfizer. Novo Nordisk dominates the market with its GLP-1 receptor agonist drugs, especially Wegovy and Ozempic, which have seen rapid adoption due to their efficacy in weight loss, driving strong sales in France and across Europe. Eli Lilly is a key competitor with its tirzepatide-based drugs Mounjaro and Zepbound, which demonstrate superior weight loss effects and are projected to outperform Novo Nordisk’s products in the near future.
Hoffmann-La Roche is also actively involved, having partnered with Zealand Pharma to develop novel anti-obesity drugs like petrelintide, targeting improved weight management and combination therapies. Pfizer has ongoing developments with GLP-1 receptor agonists such as danuglipron, though it discontinued one candidate in 2025, continuing its research pipeline for oral treatments that could increase accessibility in France and Europe. These companies are driving France's fast-growing anti-obesity drug market, projected to reach USD 742.8 million by 2030 with robust CAGR growth fueled by increasing obesity prevalence and healthcare initiatives.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
